Physician profile
Danny Wu
NPI 1235197898
$3,835.99
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $379 · 2021: $687 · 2022: $940 · 2023: $797 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,718.30 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Gilead Sciences, INC. | $706.08 | 2019-2023 | |
| Janssen Biotech, INC. | $308.80 | 2019-2023 | Stelara, Simponi Aria, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $232.22 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.96 | 2019-2023 | Trulance, Uceris |
| Qol Medical, LLC | $105.42 | 2022-2023 | Sucraid |
| Celgene Corporation | $95.13 | 2022-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $84.82 | 2023-2024 | Andexxa |
| Redhill Biopharma INC. | $59.74 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $50.24 | 2023 | |
| Braintree Laboratories, INC. | $46.44 | 2019-2022 | |
| Vivus LLC | $44.49 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $34.94 | 2019-2022 | |
| Medtronic, INC. | $31.39 | 2023 | Gi Genius |
| Ardelyx, INC. | $25.42 | 2024 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.43 | 2023 | |
| Genzyme Corporation | $19.06 | 2022 | |
| Daiichi Sankyo INC. | $18.54 | 2021 | |
| Pfizer INC. | $18.44 | 2019 | |
| Napo Pharmaceuticals INC | $15.76 | 2019 | |
| Concordia Pharmaceuticals INC. | $15.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.07 | 2023 | Rebyota |
| Ucb, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.